Delving into the Latest Updates on PhytoHealth Corp. with Synapse

Overview

Basic Info

Introduction

PhytoHealth is a pharmaceutical firm dedicated to the creation of novel drugs that adhere to global standards and regulations. The company produces an injectable medication for cancer treatment and drugs that lower the risk of cardiovascular disease. Established in 1998, PhytoHealth is a part of Maywufa Biopharma Group.

Tags

Cardiovascular Diseases

Other Diseases

Nervous System Diseases

Small molecule drug

Herbal medicine

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Neoplasms	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Herbal medicine	1
Unknown	1
Chemical drugs	1

Top 5 Target	Count

mAChRs(Muscarinic acetylcholine receptor)	1
TLR(Toll-like receptor)	1

The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative chemoradiation therapy at curative setting. This study will be designed to compare the fatigue status between two study arms patients under CCRT.
The secondary objective is to assess the efficacy of PG2 to improve the quality of life of patient during CCRT. Also, the investigators try to determine the effect of PG2 on tumor response post CCRT, disease free survival (DFS) and overall survival (OS) of patients by comparing the above outcome between the two study arms.
The mechanism of immunomodulatory of PG2 and tumor response, DFS and OS for patients with esophageal cancer treated with preoperative CCRT concurrent with or without PG2 will be investigated in add-on study.

Start Date19 Feb 2019

Sponsor / Collaborator

PhytoHealth Corp.

NCT03314805 / CompletedPhase 2

PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence. Anthracycline-based regimens, including doxorubin or epilubicin, are the breast cancer adjuvant chemotherapy standards of care. Fatigue has also been identified as the most problem for breast cancer patients under adjuvant chemotherapy. In the current study, it is aimed to show that PG2 (astragalus polysaccharides) treatment among stage II/III breast patients under adjuvant EC regimen in reduction of chemotherapy-induced toxicity and encouraging compliance with chemotherapy.

Start Date01 Mar 2018

Sponsor / Collaborator

PhytoHealth Corp.

100 Clinical Results associated with PhytoHealth Corp.

Login to view more data

0 Patents (Medical) associated with PhytoHealth Corp.

Login to view more data

5

Literatures (Medical) associated with PhytoHealth Corp.

01 Jan 2023·Frontiers in nutrition

Potential antidepressant effects of a dietary supplement from Huáng qí and its complex in aged senescence-accelerated mouse prone-8 mice.

Article

Author: Li, Po-Hsien ; Chi, Ching-Hsin ; Huang, Mao-Jung ; Wong, Yue-Ching ; Huang, Ping-Hsiu ; Chou, Ming-Yu ; Wang, Teng-Hsu ; Wang, Ming-Fu ; Wang, Shih-Yi

Healthcare is an emerging industry with significant market potential in the 21st century. Therefore, this study aimed to evaluate the benefits of tube feeding Huáng qí and its complexes for 8 weeks on 3-month-old senescence-accelerated mouse prone-8 (SAMP8) mice, 48 in total, randomly divided into 3 groups including control, Huáng qí extract [820 mg/kg Body weight (BW)/day], and Huáng qí complexes (6.2 mL /kg BW/day), where each group consisted of males (n = 8) and females (n = 8). Behavioral tests (locomotion test and aging score assessment on week 6, the single-trial passive avoidance test on week 7, and the active shuttle avoidance test on week 8) were conducted to evaluate the ability of the mice to learn and remember. In addition, after sacrificing the animals, the blood and organs were measured for antioxidant and aging bioactivities, including malondialdehyde (MDA) content and superoxide dismutase (SOD) activity and catalase activities (CAT), and the effects on promoting aging in SAMP8 mice were investigated. The findings showed that Huáng qí enhanced locomotor performance and had anti-aging effects, with positive effects on health, learning, and memory in SAMP-8 mice (p < 0.05), whether applied as a single agent (820 mg/kg BW/day) or as a complex (6.2 mL/kg BW/day) (p < 0.05). Based on existing strengths, a more compelling platform for clinical validation of human clinical evidence will be established to enhance the development and value-added of astragalus-related products while meeting the diversified needs of the functional food market.

01 Apr 2020·Materials Science and Engineering: CQ2 · ENGINEERING & TECHNOLOGY

A study of the differentiation of stem cells from human exfoliated deciduous teeth on 3D silk fibroin scaffolds using static and dynamic culture paradigms

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Ko, Chih-Sheng ; Chen, Xiao-Wei ; Su, Wen-Ta ; Wang, Guo-Shou ; Huang, Te-Yang

Stem cells from human exfoliated deciduous teeth (SHED) are considered the best current source of human stem cells due to their ability to differentiate into multiple cell lineages. Dynamic co-culture systems can improve the culture environment, as they provide cells with signaling factors, extracellular matrixes, and cellular shear force, as well as enable the formation of heterotypic clusters. We seeded SHED in 3D silk fibroin porous scaffolds under static and dynamic cultures for 28 days, using the NIH3T3 cultivated medium as an induction agent. Many hepatospheres formed in these porous scaffolds, and cellular viability was shown to continually increase by MTT assays. Hepatic AFP and ALB gene expression, as well as glycogen storage, albumin secretion, and urea synthesis, were greater in cells in the 3D porous scaffold under a dynamic culture than in those cultured under 3D static culture and petri dish conditions. However, the 3D static culture is still superior to the traditional petri dish culture. The NIH3T3 cultivated medium can significantly induce hepatic differentiation of SHED, while the 3D dynamic culture system significantly enhances hepatic differentiation of SHED. This study provides alternative sources of hepatocytes for liver disease treatment.

19 Mar 2020·Current Stem Cell Research & TherapyQ4 · MEDICINE

Stem Cells from Human Exfoliated Deciduous Teeth: A Concise Review

Q4 · MEDICINE

Review

Author: Chen, Jen-Hao ; Su, Wen-Ta ; Ko, Chih-Sheng

Stem Cells from Human Exfoliated Deciduous Teeth (SHED) originate from the embryonic neural crest as ectodermal mesenchymal stem cells and are isolated from human deciduous teeth. SHED expresses the same cell markers as Embryonic Stem Cells (ESCs), such as OCT4 and NANOG, which make SHED to have a significant impact on clinical applications. SHED possess higher rates of proliferation, higher telomerase activity, increased cell population doubling, form sphere-like clusters, and possess immature and multi-differentiation capacity; such high plasticity makes SHED one of the most popular sources of stem cells for biomedical engineering. In this review, we describe the isolation and banking method, the current development of SHED in regenerative medicine and tissue engineering in vitro and in vivo.

100 Deals associated with PhytoHealth Corp.

Login to view more data

100 Translational Medicine associated with PhytoHealth Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Sep 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Phase 3 Clinical

Approved

2

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PG2	Fatigue More	Approved
Phencynonate ( mAChRs )	Motion Sickness More	Approved
JKB-122 ( TLR )	Nonalcoholic Steatohepatitis More	Phase 3
PHN013	Purpura, Thrombocytopenic, Idiopathic More	Phase 2
PHN014	Acute Ischemic Stroke More	Clinical